Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 679.00, up by 2.70 points or 0.40 % from its previous closing of Rs. 676.30 on the BSE.

The scrip opened at Rs. 676.30 and has touched a high and low of Rs. 680.75 and Rs. 666.60 respectively. So far 124411 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 700.00 and Rs. 660.00 respectively. The current market cap of the company is Rs. 162444.95 crore.

The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 33.34% and 11.68% respectively.

Sun Pharma and Israel-based Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis. MM-II is a novel non-opioid product that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction.

According to the agreement, Sun Pharma will fund further development of Moebius Medical’s lead product, MM-II, and undertake its global commercialization. To date, Moebius Medical has completed a first-in-man clinical study at Hadassah Medical Center, demonstrating the product’s fast onset of action and its potentially better efficacy and comparable safety for alleviating osteoarthritis pain as compared to Hyaluronic Acid injection.

Sun Pharmaceutical Industries is a pharmaceuticals company. The company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API).